Restores impaired axonal transport to normal levels, targeting Phase 1 clinical entry by late 2026
[by Yu, Suin] Chong Kun Dang announced on December 3 that it had presented preclinical study findings for its neurological disorder treatment candidate, ‘CKD-513 (development code),’ in a poster presentation at the 2025 Society for Neuroscience Annual Meeting held in California, USA.
CKD-513 is a novel therapeutic candidate designed to directly improve neuronal function by selectively inhibiting HDAC6, an enzyme that destabilizes microtubules in neurons and disrupts axonal transport. The candidate markedly improves brain penetration, addressing the limitations associated with existing HDAC6 inhibitors. It is currently under development for the treatment of 카지노 바카라 disorders, including Alzheimer's disease, tauopathies, and Charcot-Marie-Tooth disease (CMT).
The presentation introduced efficacy data generated in a tauopathy model, a degenerative central nervous system disorder. Tauopathy is a degenerative brain disease characterized by the abnormal accumulation of tau protein within neurons, resulting in impaired neuronal function, and is known to play a major role in the development of various 카지노 바카라 diseases, including Alzheimer's disease.
Non-clinical studies demonstrated that 카지노 바카라513 exhibits strong selectivity for HDAC6 and excellent brain permeability. The candidate also restored impaired axonal transport to normal levels in tau-overexpressing cells and in animal models of the disease. According to the company, the drug further produced improvements in cognition and memory in these models, while long-term potentiation (LTP) assessments confirmed improved neuronal function.
"This presentation marks a significant milestone, demonstrating the new potential of our HDAC6 inhibition platform technology. Building on the improvements in neuronal function observed in tauopathy and Charcot-Marie-Tooth disease models, we plan to further accelerate our research and development (R&D) efforts in the field of 카지노 바카라 disorders," a Chong Kun Dang official said.
카지노 바카라513 was recently selected as a national project by the Korea Drug Development Fund (KDDF) and is currently receiving support for preclinical research. Development is scheduled to proceed with the objective of entering Phase 1 clinical trials by the end of 2026. The KDDF is an inter-ministerial national R&D initiative launched to strengthen the global competitiveness of the Korean pharmaceutical and biotechnology industries. Launched in 2021, the program supports the full lifecycle of new drug development over a ten-year period, with the goals of reinforcing the domestic novel drug R&D ecosystem, generating globally competitive commercialization results, and contributing to the advancement of the public health and medical sectors.